Risk Factors for Community-Associated Infection in Adults: A Case-Control Study
Overview
Authors
Affiliations
Background: An increasing proportion of infections (CDI) in the United States are community-associated (CA). We conducted a case-control study to identify CA-CDI risk factors.
Methods: We enrolled participants from 10 US sites during October 2014-March 2015. Case patients were defined as persons age ≥18 years with a positive specimen collected as an outpatient or within 3 days of hospitalization who had no admission to a health care facility in the prior 12 weeks and no prior CDI diagnosis. Each case patient was matched to one control (persons without CDI). Participants were interviewed about relevant exposures; multivariate conditional logistic regression was performed.
Results: Of 226 pairs, 70.4% were female and 52.2% were ≥60 years old. More case patients than controls had prior outpatient health care (82.1% vs 57.9%; < .0001) and antibiotic (62.2% vs 10.3%; < .0001) exposures. In multivariate analysis, antibiotic exposure-that is, cephalosporin (adjusted matched odds ratio [AmOR], 19.02; 95% CI, 1.13-321.39), clindamycin (AmOR, 35.31; 95% CI, 4.01-311.14), fluoroquinolone (AmOR, 30.71; 95% CI, 2.77-340.05) and beta-lactam and/or beta-lactamase inhibitor combination (AmOR, 9.87; 95% CI, 2.76-340.05),-emergency department visit (AmOR, 17.37; 95% CI, 1.99-151.22), white race (AmOR 7.67; 95% CI, 2.34-25.20), cardiac disease (AmOR, 4.87; 95% CI, 1.20-19.80), chronic kidney disease (AmOR, 12.12; 95% CI, 1.24-118.89), and inflammatory bowel disease (AmOR, 5.13; 95% CI, 1.27-20.79) were associated with CA-CDI.
Conclusions: Antibiotics remain an important risk factor for CA-CDI, underscoring the importance of appropriate outpatient prescribing. Emergency departments might be an environmental source of CDI; further investigation of their contribution to CDI transmission is needed.
Schley K, Heinrich K, Moisi J, Hackl D, Obermuller D, Brestrich G Infect Dis Ther. 2024; 14(1):91-104.
PMID: 39565511 PMC: 11782737. DOI: 10.1007/s40121-024-01075-1.
A call to action: the SHEA research agenda to combat healthcare-associated infections.
Kwon J, Advani S, Branch-Elliman W, Braun B, Cheng V, Chiotos K Infect Control Hosp Epidemiol. 2024; 1-18.
PMID: 39448369 PMC: 11518679. DOI: 10.1017/ice.2024.125.
Bacterial metabolites influence the autofluorescence of .
Ticer T, Tingler A, Glover J, Dooley S, Kendrick J, Zackular J Front Microbiol. 2024; 15:1459795.
PMID: 39439940 PMC: 11493716. DOI: 10.3389/fmicb.2024.1459795.
Baghdadi J, Wessel M, Dubberke E, Lydecker A, Claeys K, Alonso C Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e168.
PMID: 39411667 PMC: 11474763. DOI: 10.1017/ash.2024.387.
Beyond Antibiotics: Novel Approaches in the Treatment of Recurrent Infection.
Zaidi S, Haider R, Kazmi S, Husnain A, Khan S, Merchant S ACG Case Rep J. 2024; 11(8):e01333.
PMID: 39081300 PMC: 11286250. DOI: 10.14309/crj.0000000000001333.